Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed) (351176)

    From US Department of Health & Human Services: National Institutes of Health (NIH)

    The National Institutes of Health (NIH), a part of the U.S. Department of Health and Human Services, is the nation’s medical research agency — making important discoveries that improve health and save lives.

    Type of Support

    Overview

    The grant aims to support exploratory research projects that focus on the development and validation of emerging technologies designed to improve the quality of samples for cancer research or clinical care. It targets new capabilities to mitigate pre-analytical degradation of targeted analytes in biospecimens related to cancer. The grant seeks applications for technologies that have passed initial feasibility tests, as shown by preliminary data, yet require further development and rigorous validation for wider adoption. The objective is to foster the creation of innovative technologies that maximize the utility and quality of biological samples for subsequent analysis. This includes the development of tools, devices, instrumentation, and methods to preserve sample integrity or establish quality control criteria, aiming to boost cancer research, enhance early detection, clinical diagnosis, treatment, and epidemiology, and address cancer health disparities by minimizing pre-analytical variations that compromise biospecimen quality.

    Eligibility

    Organization's Location
    id in
    Program Location
    eu
    Organization Type

    Submission

    Visit Apply for more information.
    2 of 2 free pages viewed this month
    Sign up to view this and 12k+ more grant opportunities
    or
    Already have an account?Log in